Stay updated on Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial.

Sign up to get notified when there's something new on the Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial. page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial. page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    The page's revision label was updated from v3.6.2 to v3.6.3, signaling a minor update to the content or metadata on the study details page.
    Difference
    0.0%
    Check dated 2026-07-04T14:36:25.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    - Revision updated from v3.6.0 to v3.6.2 on the page, signaling a new release/version behind the scenes. This does not appear to change the visible study details or user-facing content.
    Difference
    0.0%
    Check dated 2026-06-27T10:36:14.000Z thumbnail image
  4. Check
    32 days ago
    Change Detected
    Summary
    Recruitment status updated to 'No longer looking for participants'; the page's intervention labeling and related headers were updated (Intervention/Treatment added and Intervention / Treatment removed) as part of Revision v3.6.0.
    Difference
    0.1%
    Check dated 2026-06-12T00:49:00.000Z thumbnail image
  5. Check
    39 days ago
    Change Detected
    Summary
    Kharkiv Oblast location was added with the city Kharkiv, Kharkiv Oblast, Ukraine, 61070. The previous Kharkivs’ka Oblast’ entry (Kharkiv, Kharkivs’ka Oblast’, Ukraine, 61070) was removed.
    Difference
    0.0%
    Check dated 2026-06-05T00:18:01.000Z thumbnail image
  6. Check
    54 days ago
    Change Detected
    Summary
    The page's revision tag updated from v3.5.3 to v3.5.4, indicating a backend or documentation update. The study content and user-facing information appear unchanged.
    Difference
    0.0%
    Check dated 2026-05-21T16:26:19.000Z thumbnail image
  7. Check
    68 days ago
    Change Detected
    Summary
    The Taiwan site entry changes from Taoyuan District to Taoyuan, standardizing the city name in the study's locations. The postal code remains associated with the site.
    Difference
    0.0%
    Check dated 2026-05-07T09:45:21.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial.

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial. page.